September 2, 2009

Harvard Medical School Study Finding Confirms the Presence of DispersinB(R) Biofilm Target in Combat Wound Infection-Associated Bacteria

WINNIPEG, MANITOBA -- (MARKET WIRE) -- 09/02/09 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce a recent research publication by Harvard Medical School on their finding of DispersinB® enzyme specific substrate in Acinetobacter baumannii (A. baumannii). The manuscript appeared in the latest online edition of the Journal of Bacteriology (doi: 10.1128/JB.00647-09).

The publication, entitled "The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-Beta-1-6-N-acetyl glucosamine PNAG that is critical for biofilm formation" by Choi, A.H.K. et al., confirms that pgaABCD genes encode the production of PNAG, which is needed for biofilm formation in combat wound and hospital-acquired infection associated pathogen A. baumannii.

"Our study shows that A. baumannii contains pgaABCD genes that encode proteins required for the biosynthesis of PNAG polysaccharide, which is essential for biofilm formation," stated Dr. Tomas Maira-Litran, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston. "Biofilm-dependent production of PNAG could be an important virulence factor for this emerging pathogen that has a few known virulence factors," added Dr. Maira-Litran.

Dr. Sri Madhyastha, Vice President-Research & Chief Scientific Officer of Kane Biotech, commented on the findings stating, "Since the PNAG polysaccharide in A. baumannii and other Acinetobacter species biofilms is a specific substrate for the activity of the DispersinB® enzyme, DispersinB® will prevent as well as disperse Acinetobacter biofilms. DispersinB® can be used in medical device coatings and wound care products for prevention as well as treatment of combat wound and hospital-acquired infections involving Acinetobacter baumannii, an emerging bacterial pathogen".

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as medical

device and wound associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

Contacts:
Kane Biotech Inc.
Gord Froehlich
President & Chief Executive Officer
204-477-7592
204-453-1314 (FAX)
ir@kanebiotech.com
www.kanebiotech.com